Form 4: Whitehawk Therapeutics Executive Sells Shares for Taxes

Chief Technical Operations Officer Bryan Ball sold 118,849 shares of Whitehawk Therapeutics to cover tax obligations.

Summary

• Bryan Ball, Chief Technical Operations Officer and SVP of Manufacturing Operations, sold a total of 118,849 shares of Whitehawk Therapeutics (WHWK) common stock.
• The sales occurred on April 13, 2026 (26,389 shares at $3.46) and April 14, 2026 (92,460 shares at $3.64).
• The transactions were executed to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, the reporting person retains beneficial ownership of 397,106 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is purely administrative and related to tax obligations rather than a discretionary divestment.

Positives

• The sale was non-discretionary, specifically executed to satisfy tax withholding requirements upon the vesting of equity awards.

Negatives

• The transaction represents a reduction in the executive's direct equity stake in the company.

Risks

• None identified; this is a routine administrative transaction related to tax compliance.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Management Comments

• The filing notes that the sale was a broker-assisted transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding purposes are standard corporate practice and generally do not signal a change in management sentiment regarding the company's long-term prospects.

Comparison to Industry Standards

• The transaction aligns with standard industry practices for executive compensation management where equity vesting triggers automatic tax withholding sales.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned for tax compliance.

Next Steps

• None indicated.

Key Dates

Keywords

Whitehawk Therapeutics, WHWK, Insider Trading, Form 4, SEC Filing, Equity Vesting, Tax Withholding